RHHBF - Sarepta, Replimmune, Capricor rise as FDA's biologics head departs
2025-07-30 10:27:30 ET
More on Sarepta, Capricor, etc.
- Sarepta Therapeutics: Beaten Down, But Not Out
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
- FDA vaccines head, chief medical officer Vinay Prasad departs agency
- Sarepta upgraded to Neutral at J.P. Morgan, Outperform at Oppenheimer